Literature DB >> 22116598

High-dose immunoglobulin preparations improve survival in a CLP-induced rat model of sepsis.

Takahisa Yoshikawa1, Hiroya Takeuchi, Koichi Suda, Taku Miyasho, Shingo Yamada, Minoru Okamoto, Yoshio Kawamura, Ikuro Maruyama, Masaki Kitajima, Yuko Kitagawa.   

Abstract

PURPOSE: The efficacy of intravenous immunoglobulin G in the treatment of patients with severe sepsis or septic shock is still being debated. We investigated the impact of high-dose immunoglobulin administration on the survival rate and serum high-mobility group box chromosomal protein 1 (HMGB1) level in a rat model of sepsis created by cecal ligation and puncture (CLP).
METHODS: Rats received either CLP-induced sepsis or had additional immunoglobulin treatment in 1,500 or 300 mg/kg. After induction of sepsis and respective treatment conditions, pulmonary and renal tissues were examined histologically for pathological changes at postoperative hour (POH) 4, and serum cytokine and HMGB1 levels were measured at POH 4, 8, 20, and 44. Using other rats, we also observed the survival rate after CLP for 7 days.
RESULTS: Treatment with immunoglobulin significantly improved survival rate at postoperative day 7 (73% in the high-dose group vs. 33% in the control group; p = 0.037). The serum lactate dehydrogenase, endotoxin, creatinine, and blood urea nitrogen levels were significantly lower in the high-dose group than in the other groups. The serum HMGB1 level had increased at 4 h postoperatively in the control group (10.2 ± 3.3 ng/mL) and low-dose group (10.3 ± 4.0 ng/mL), but it was significantly reduced in the high-dose group (4.2 ± 0.8 ng/mL) compared with the control group (p = 0.03).
CONCLUSIONS: Our results suggest that high-dose immunoglobulin therapy may improve the serum endotoxin and HMGB1 levels and overall survival rate in sepsis by inhibiting the inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22116598     DOI: 10.1007/s00423-011-0878-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  33 in total

Review 1.  Another interaction of the FcR system with IVIG.

Authors:  James B Bussel
Journal:  Thromb Haemost       Date:  2002-12       Impact factor: 5.249

2.  Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-17       Impact factor: 17.440

Review 3.  Anti-inflammatory actions of intravenous immunoglobulin.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

4.  Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminated intravascular coagulation in rats.

Authors:  Hidesaku Asakura; Yoko Takahashi; Anna Kubo; Yasuo Ontachi; Tomoe Hayashi; Mika Omote; Masahisa Arahata; Yasuko Kadohira; Mio Maekawa; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Tomotaka Yoshida; Ken-Ichi Miyamoto; Shinji Nakao
Journal:  Crit Care Med       Date:  2006-09       Impact factor: 7.598

Review 5.  Sepsis and septic shock--a review of laboratory models and a proposal.

Authors:  K A Wichterman; A E Baue; I H Chaudry
Journal:  J Surg Res       Date:  1980-08       Impact factor: 2.192

6.  Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery.

Authors:  Alejandro Rodríguez; Jordi Rello; Jorge Neira; Bernardo Maskin; Daniel Ceraso; Leonardo Vasta; Fernando Palizas
Journal:  Shock       Date:  2005-04       Impact factor: 3.454

7.  Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness.

Authors:  Josef G Heuer; Dianna L Bailey; Ganesh R Sharma; Tonghai Zhang; Chunjin Ding; Amy Ford; Eddie J Stephens; Kimberly C Holmes; Renee L Grubbs; Kelly A Fynboe; Yun-Fei Chen; Joseph A Jakubowski
Journal:  J Surg Res       Date:  2004-10       Impact factor: 2.192

8.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

9.  Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis.

Authors:  Koichi Suda; Hiroya Takeuchi; Tomoko Hagiwara; Taku Miyasho; Minoru Okamoto; Kazufumi Kawasako; Shingo Yamada; Kazuhiro Suganuma; Norihito Wada; Yoshiro Saikawa; Koichi Fukunaga; Yosuke Funakoshi; Satoru Hashimoto; Hiroshi Yokota; Ikuro Maruyama; Akitoshi Ishizaka; Yuko Kitagawa
Journal:  Shock       Date:  2010-05       Impact factor: 3.454

Review 10.  Extracellular role of HMGB1 in inflammation and sepsis.

Authors:  H Wang; H Yang; K J Tracey
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989

View more
  1 in total

Review 1.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.